Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy DexCom (DXCM) stocks
Learn how to easily invest in DexCom stocks.
DexCom is a medical devices business based in the US. DexCom stocks (DXCM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $119.71 – an increase of 0.11% over the previous week. DexCom employs 7,500 staff and has a trailing 12-month revenue of around $3 billion.
How to buy DexCom stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – DXCM. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
What's in this guide?
- Can I buy shares in DexCom?
- Has coronavirus impacted DexCom shares?
- DexCom shares summary
- Compare share dealing platforms
- Is DexCom stock a buy or sell?
- DexCom performance over time
- Is DexCom suitable for ethical investing?
- Are DexCom shares over-valued?
- DexCom's financials
- How volatile are DexCom shares?
- Does DexCom pay a dividend?
- Have DexCom shares ever split?
- Other common questions
DexCom stock price (NASDAQ:DXCM)Use our graph to track the performance of DXCM stocks over time.
DexCom shares at a glance
|Latest market close||$119.71|
|52-week range||$67.11 - $126.44|
|50-day moving average||$118.07|
|200-day moving average||$108.48|
|Wall St. target price||$140.70|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.73|
Buy DexCom stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy DexCom stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
DexCom price performance over time
Historical closes compared with the close of $119.71 from 2023-06-07
|1 week (2023-06-01)||0.11%|
|1 month (2023-05-08)||-0.39%|
|3 months (2023-03-04)||N/A|
|6 months (2022-12-04)||N/A|
|1 year (2022-06-06)||-59.60%|
|2 years (2021-06-04)||N/A|
|3 years (2020-06-08)||368.62|
|5 years (2018-06-08)||28.72%|
Is DexCom stock undervalued or overvalued?
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's P/E ratio
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 168x. In other words, DexCom shares trade at around 168x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's PEG ratio
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 11.3373. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $541.4 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3 billion|
|Operating margin TTM||13.14%|
|Gross profit TTM||$1.9 billion|
|Return on assets TTM||4.7%|
|Return on equity TTM||13.23%|
|Market capitalisation||$47.5 billion|
TTM: trailing 12 months
DexCom's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
DexCom's total ESG risk score
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 01/01/2019) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
DexCom's environmental score
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
DexCom's social score
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
DexCom's governance score
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
DexCom's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
DexCom share dividends
We're not expecting DexCom to pay a dividend over the next 12 months.
Have DexCom's shares ever split?
DexCom's shares were split on a 4:1 basis on 13 June 2022. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.
DexCom share price volatility
Over the last 12 months, DexCom's shares have ranged in value from as little as $67.11 up to $126.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.1531. This would suggest that DexCom's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
Stocks similar to DexCom
DexCom in the news
Dow Jones Rises After Surprise Jump In Jobless Claims; GME Stock Crashes 22% After Firing CEO
Dexcom to Host Investor Day on June 23, 2023
Dow Jones Giant McDonald's Tests Key Support Level; Tesla Stock In Buy Range
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
Bad credit loans in Edmonton, Alberta
From personal and payday loans to lines of credit, compare loans for bad credit in Edmonton.
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
How to buy Pepe (PEPE) in Canada
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
How to buy Arbitrum (ARB) in Canada
This guide provides step-by-step instructions on how to buy Arbitrum, lists some exchanges where you can get it and provides daily price data on (ARB).
How to buy SSV Network (SSV) in Canada
This guide provides step-by-step instructions on how to buy SSV Network, lists some exchanges where you can get it and provides daily price data on (SSV).
How to buy USDD (USDD) in Canada
This guide provides step-by-step instructions on how to buy USDD, lists some exchanges where you can get it and provides daily price data on (USDD).
How to buy Blur (BLUR) in Canada
This guide provides step-by-step instructions on how to buy Blur, lists some exchanges where you can get it and provides daily price data on (BLUR).
How to buy FLOKI Inu (FLOKI) in Canada
This guide provides step-by-step instructions on how to buy FLOKI Inu, lists some exchanges where you can get it and provides daily price data on (FLOKI).
How to buy Aptos (APT) in Canada
This guide provides step-by-step instructions on how to buy Aptos, lists some exchanges where you can get it and provides daily price data on (APT).
How to buy EthereumPoW (ETHW) in Canada
This guide provides step-by-step instructions on how to buy EthereumPoW, lists some exchanges where you can get it and provides daily price data on (ETHW).